Cognition Therapeutics (CGTX) Shares Outstanding (Diluted Average) (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $89.2 million in Q1 2026.

• Quarterly Shares Outstanding (Diluted Average) rose 44.26% year-over-year to $89.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.2 million (up 44.26% YoY) and the FY2025 annual result came in at $72.8 million, up 83.15% from the prior year.
• Shares Outstanding (Diluted Average) climbed to $89.2 million in Q1 2026 per CGTX's latest filing, from $72.8 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $89.2 million in Q1 2026 and bottomed at $22.4 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $33.7 million (2024), against an average of $42.8 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Diluted Average) surged 3976.34%; it then increased 15.95% in 2024.
• Tracing CGTX's Shares Outstanding (Diluted Average) over 5 years: stood at $23.6 million in 2022, then advanced by 27.03% to $30.0 million in 2023, then soared by 32.31% to $39.7 million in 2024, then soared by 83.15% to $72.8 million in 2025, then increased by 22.57% to $89.2 million in 2026.
• Per Business Quant, the three latest CGTX Shares Outstanding (Diluted Average) figures stand at $89.2 million (Q1 2026), $72.8 million (Q4 2025), and $78.0 million (Q3 2025).

Peer Comparison